Pharminent

FDA grants accelerated approval to Rybrevant Faspro in head and neck cancer

The FDA granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed on or after platinum-based chemotherapy.

European Commission expands Jyseleca approval to axial spondyloarthritis

Alfasigma received expanded European Commission approval for Jyseleca (filgotinib) to treat adult patients with active axial spondyloarthritis.

NICE and NHS England pilot six-month appraisal for new medicines

NICE and NHS England are piloting a shorter initial assessment process for promising new medicines, aiming to cut appraisal times from 12 months to six.

MHRA sets out patient and public involvement plan for 2026-2030

The MHRA published a patient and public involvement and engagement (PPIE) plan for 2026-2030, under which it will consider a diverse range of patient and public opinions when making regulatory decisions.

Moderna and Oxford Ebola vaccines backed for pivotal DRC trial

Ebola vaccines from Moderna and the University of Oxford are set to be added to a trial in the Democratic Republic of the Congo, which is battling its largest-ever outbreak.

J&J and AbbVie to present early trispecific antibody data at ASH

Johnson & Johnson and AbbVie are among the drugmakers set to showcase early data at ASH for trispecific antibodies in multiple myeloma.

Armada Acquisition to combine with Brains Bioceutical in $750M deal

Armada Acquisition entered a definitive business combination agreement with Brains Bioceutical, valuing Brains Bioceutical at an implied pre-money equity value of $750 million.

Rezera sets terms for IPO seeking more than $200M

Rezera, formerly known as NodThera, announced terms for its planned IPO, aiming to raise upwards of $200 million for its NLRP3 inhibitor pipeline.

Egetis sells priority review voucher for $190 million

Egetis has sold a priority review voucher for $190 million.